Immunisation Return on Investment Model
Development of a return on investment (ROI) model to demonstrate the benefit of increasing adult vaccination coverage rates (VCRs)
Despite worldwide success in terms of increasing public health, vaccination programmes often face scepticism and hesitancy. Moreover, adult vaccination programmes, especially prior to COVID-19, received less consideration compared to paediatric programmes.
Therefore, our client required a ROI model to demonstrate the value of increasing VCRs in populations >50 years old across the EU4, Greece, the UK and the US for:
> Herpes zoster
> Pneumococcal disease
> Respiratory syncytial virus (RSV)
In order to demonstrate the value of investing in adult vaccination programmes, two key stages were undertaken for each country. First, a structured literature review was undertaken to identify model inputs. Secondly, the ROI model was developed in a flexible manner, maximising user friendliness and ensuring value messages were presented in a visually impactful way.
The ROI tool enabled the user to explore:
> The economic return for every €1/£1/$1 invested in increased VCRs compared to the current VCRs.
> The break-even point, i.e. where savings from prevented illness met the cost of implementing an increased VCR strategy.
> The number of quality-adjusted life years (QALYs) and life years (LYs) gained as well as disease cases, deaths and antimicrobial resistance cases averted in the increased vs. current vaccination strategy.
Value to the client
The ROI tool demonstrated that costs associated with increased adult immunisation programmes are a good investment. Furthermore, it predicted the total economic benefit of increased adult vaccination over time. The model proved useful to our client in terms of internal strategies and demonstrating the importance of expanding VCRs to policymakers.